A
41.03
0.00 (0.00%)
| Penutupan Terdahulu | 41.03 |
| Buka | 41.03 |
| Purata Dagangan (3B) | 6,474,715 |
| Modal Pasaran | 5,252,712,960 |
| Harga / Pendapatan (P/E TTM) | 38.35 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 30 Jul 2026 |
| Margin Keuntungan | -28.83% |
| Margin Operasi (TTM) | -49.96% |
| EPS Cair (TTM) | -1.80 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -3.20% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 285.94% |
| Nisbah Semasa (MRQ) | 4.08 |
| Aliran Tunai Operasi (OCF TTM) | -8.29 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 45.63 M |
| Pulangan Atas Aset (ROA TTM) | -14.20% |
| Pulangan Atas Ekuiti (ROE TTM) | -103.82% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Apellis Pharmaceuticals, Inc. | Bercampur | Menurun |
Saham Serupa
| Stok | Modal Pasaran | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| APLS | 5 B | - | 38.35 | - |
| TERN | 6 B | - | - | 6.08 |
| TRML | 1 B | - | - | 4.76 |
| SVRA | - | - | - | 9.38 |
| IONS | - | - | - | 11.92 |
| VKTX | - | - | - | 6.21 |
AISkor Stockmoo
| Nilai 35% | -0.5 |
| AI Insight info | NA |
| Penilaian Relatif info | NA |
| Kesihatan Kewangan info | -0.5 |
| Masa 35% | 0.0 |
| AI Technical info | NA |
| Osilator Teknikal info | 0.0 |
| Purata Bergerak Teknikal info | 0.0 |
| Wang Pintar 30% | 0.0 |
| Konsensus Penganalisis info | 0.0 |
| Aktiviti Orang Dalam info | NA |
| Sentimen Berita info | NA |
| Persekitaran | ×1.21 |
| Persekitaran Makro info | -3.3 |
| Sektor berbanding Pasaran (6B) | -22.4% |
| Persetujuan Tonggak | ×1.00 |
| Tidak dikira dalam skor | |
| Volatiliti Harga info | -2.5 |
| Skor Akhir | -0.21 |
|
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 13.69% |
| % Dimiliki oleh Institusi | 104.60% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |